Table 1

Baseline demographic and disease characteristics of patients with and without enthesitis

With enthesitis at baselineWithout enthesitis at baseline
PlaceboGuselkumabTotalPlaceboGuselkumabTotal
Patients, n3176107182442
Age, years46.0 ± 12.748.0 ± 12.447.4 ± 12.541.0 ± 11.645.4 ± 14.243.5 ± 13.2
Male14 (45.2)35 (46.1)49 (45.8)10 (55.6)27 (70.8)27 (64.3)
Weight, kg85.0 ± 16.585.6 ± 23.185.4 ± 21.388.6 ± 26.580.6 ± 14.684.0 ± 20.6
SJC (0–66)12.4 ± 8.712.6 ± 7.312.5 ± 7.77.4 ± 2.99.8 ± 8.48.8 ± 6.7
TJC (0–68)25.2 ± 12.522.7 ± 12.023.4 ± 12.111.3 ± 5.914.6 ± 10.713.2 ± 9.0
CRP, mg/dL2.0 ± 2.51.9 ± 2.51.9 ± 2.51.5 ± 2.21.6 ± 2.21.6 ± 2.2
HAQ-DI1.50 ± 0.441.48 ± 0.601.49 ± 0.561.06 ± 0.601.22 ± 0.661.15 ± 0.63
PsA duration, years7.5 ± 7.77.0 ± 7.37.1 ± 7.45.9 ± 6.46.9 ± 7.26.5 ± 6.8
Patients with dactylitis14 (45.2)45 (59.2)59 (55.1)9 (50.0)13 (54.2)22 (52.4)
Dactylitis score2.1 ± 3.34.1 ± 5.93.5 ± 5.41.4 ± 1.82.7 ± 4.72.2 ± 3.8
Patients with enthesitis31 (100)76 (100)107 (100)000
Enthesitis score2.6 ± 1.52.7 ± 1.52.7 ± 1.5
BSA, %12.8 ± 12.716.5 ± 15.215.5 ± 14.514.8 ± 12.519.5 ± 16.917.5 ± 15.2
PASI (0–72)9.9 ± 8.512.0 ± 10.711.4 ± 10.19.9 ± 7.212.1 ± 10.211.1 ± 9.0
Previous anti-TNF therapy2 (6.5)8 (10.5)10 (9.3)2 (11.1)2 (8.3)4 (9.5)
Baseline medication use
MTX7 (22.6)34 (44.7)41 (38.3)12 (66.7)13 (54.2)25 (59.5)
Oral corticosteroids4 (12.9)10 (13.2)14 (13.1)4 (22.2)2 (8.3)6 (14.3)
NSAIDs23 (74.2)52 (68.4)75 (70.1)13 (72.2)18 (75.0)31 (73.8)
  • Data presented as n (%) or mean ± SD unless otherwise noted.

  • BSA, body surface area; CRP, C reactive protein; HAQ-DI, Health Assessment Questionnaire-Disability Index; MTX, methotrexate; NSAIDs, non-steroidal anti-inflammatory drugs; PASI, Psoriasis Area and Severity Index; PsA, psoriatic arthritis; SJC, swollen joint count; TJC, tender joint count; TNF, tumour necrosis factor.